Scientific Articles Related to CBD and Epilepsy and Seizures
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE4)
Summary: A randomised, double-blind, placebo-controlled phase 3 trial found that cannabidiol is efficacious for the treatment of patients with drop seizures associated with Lennox-Gastaut syndrome and is generally well tolerated. The long-term efficacy and safety of cannabidiol is currently being assessed in the open-label extension of this trial.
Cannabinoids for epilepsy.
Summary: A Cochrane review was conducted in 2012 to assess the safety and efficacy of cannabinoid use in patients with epilepsy. The authors summarized the finding that a CBD dose of 200 mg to 300 mg daily was safely administered over a short period. The only reasonable conclusion made was that the efficacy of CBD use could not be confirmed, but the rate of adverse reactions in each of the studies was low over a short period.
Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
Summary: In phase 1 of the study, 3 mg/kg daily of cannabidiol (CBD) was given for 30 days to 8 healthy human volunteers. All patients and volunteers tolerated CBD very well and no signs of toxicity or serious side effects were detected on examination. 4 of the 8 CBD subjects remained almost free of convulsive crises throughout the experiment and 3 other patients demonstrated partial improvement in their clinical condition. CBD was ineffective in 1 patient. The clinical condition of 7 placebo patients remained unchanged whereas the condition of 1 patient clearly improved. The potential use of CBD as an antiepileptic drug and its possible potentiating effect on other antiepileptic drugs are discussed.
Read full article.
Leave a comment
Comments will be approved before showing up.